Delisting riskPopularity #5,375
GDTC · NASDAQ · Biotechnology

CytoMed Therapeutics (GDTC)

Develops donor-derived and iPSC-based cell therapies for cancer.

$0.9082
vs last close−0.00 (−0.20%)

Something off on this page? Send us feedback.

Next report
Nov 13, 26
estimated · in 51 days
EPS estimate
Revenue estimate
$144.4K
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Feb '24Apr '24Jun '24Sep '24Apr '25Sep '25Mar '26Nov '26
Reported−$0.06−$0.03−$0.05−$0.07−$0.07−$0.07−$0.11Pending
Estimate−$0.02−$0.03−$0.04
Surprise−57.7%−133.3%−76.7%

RevenueReportedEstimate

Feb '24Apr '24Jun '24Sep '24Apr '25Sep '25Mar '26Nov '26
Reported$84.6K$83.1K$61.0K$82.7K$100.0K$105.7K$130.5KPending
Estimate$115.3K$156.0K$130.0K$144.4K
Surprise−28.0%−47.0%−23.0%

HistoryUpcoming

Date / PeriodEstimateReportedSurprise
Nov 2026$0.00
Jun 2026
May 2026
Mar 2026−$0.11
Sep 2025−$0.07
Apr 2025−$0.04−$0.07−76.7%
Sep 2024−$0.03−$0.07−133.3%
Jun 2024
Apr 2024
Feb 2024
Nov 2023
Sep 2023
Jun 2023
May 2023
Nov 2022
Sep 2022
Jun 2022
Mar 2022
Dec 2021
Sep 2021
Jun 2021
Mar 2021
Dec 2020
Sep 2020
Jun 2020
Mar 2020

The latest year is open to everyone — the 19 quarters behind it read with an account.

Date / PeriodEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 13, 2026$0.00$144.4K
Jun 30, 2026
May 4, 2026
Mar 31, 2026−$0.11$130.5K+3.0%
Sep 30, 2025−$0.07$105.7K+1.0%
Apr 28, 2025−$0.04−$0.07−76.7%$130.0K$100.0K−23.0%−1.2%
Sep 30, 2024−$0.03−$0.07−133.3%$156.0K$82.7K−47.0%+4.5%
Jun 30, 2024
Apr 22, 2024
Feb 28, 2024
Nov 17, 2023
Sep 30, 2023
Jun 30, 2023
May 1, 2023
Nov 18, 2022
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021
Sep 30, 2021
Jun 30, 2021
Mar 31, 2021
Dec 31, 2020
Sep 30, 2020
Jun 30, 2020
Mar 31, 2020

The latest year is open to everyone — the 19 quarters behind it read with an account.